Xenon Pharmaceuticals (XENE) Common Equity (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Common Equity data on file, last reported at $1.3 billion in Q1 2026.

• On a quarterly basis, Common Equity rose 90.04% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 90.04% increase from a year earlier, with the FY2025 full-year figure at $581.8 million, down 22.94% from the prior year.
• Common Equity for Q1 2026 stood at $1.3 billion, up from $581.8 million in the prior quarter.
• Over the last five years, Common Equity for XENE reached as high as $1.3 billion in Q1 2026 and fell as low as $541.9 million in Q1 2022.
• Historically, Common Equity has averaged $753.0 million across 5 years, with a median of $721.5 million in 2022.
• Across the five-year window, Common Equity jumped 205.78% in 2022 and slipped 29.87% in 2025, its largest moves.
• Year by year, Common Equity stood at $721.5 million in 2022, then gained by 28.61% to $927.9 million in 2023, then slipped by 18.65% to $754.9 million in 2024, then fell by 22.94% to $581.8 million in 2025, then soared by 129.96% to $1.3 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $1.3 billion in Q1 2026, $581.8 million in Q4 2025, and $559.5 million in Q3 2025.